Acute respiratory distress syndrome after rituximab infusion

International Journal of Hematology

Volumn 82, Issue 4, 2005, Pages 324-326

  Montero, Alberto J ^a   McCarthy, John J ^a   Chen, George ^a   Rice, Lawrence ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acute respiratory distress syndrome; Immune thrombocytopenic purpura; Monoclonal antibody; Rituximab

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; DANAZOL; GEMTUZUMAB OZOGAMICIN; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; OKT 3; RITUXIMAB;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INDICATION; DRUG SAFETY; DYSPNEA; HUMAN; HYPOXEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; PATIENT SELECTION; RISK BENEFIT ANALYSIS; THORAX PAIN;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; HUMANS; LYMPHOMA; MALE; RADIOGRAPHY, THORACIC; RESPIRATORY DISTRESS SYNDROME, ADULT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33644664959     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.NA0506     Document Type: Article

References (23)

1. Dillman RO. Magic bullets at last! Finally-approval of a monoclonal antibody for the treatment of cancer! Cancer Biother Radiopharm. 1997;12:223-225.
2. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232-239.
3. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952-927.
4. Bussel JB. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol. 2000;37:261-266.
5. Kojouri K, George JN. Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura. Int J Hematol. 2005;81:119-125.
6. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18:465-471.
7. Saito B, Nakamaki T, Adachi D, Suzuki J, Tomoyasu S. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol. 2004;80:164-167.
8. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17:791-795.
9. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003;348:2690-2691.
10. Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol. 2005;81:169-170.
11. Jullien V, Perrin C, Peyrade F, Lemoigne F, Chichmanian RM, Blaive B. Alveolar hypoxemic interstitial pneumonia related to rituximab therapy [in French]. Rev Mal Respir. 2004;21:407-410.
12. Swords R, Power D, Fay M, O'Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol. 2004;77:103-104.
13. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-1349.
14. Frey DJ, Matas AJ, Gillingham KJ, et al. Sequential therapy: a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation. 1992;54:50-56.
15. Bamgbola FO, Del Rio M, Kaskel FJ, Flynn JT. Non-cardiogenic pulmonary edema during basiliximab induction in three adolescent renal transplant patients. Pediatr Transplant. 2003;7:315-320.
16. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
17. Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV Jr. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. 2002;8:186-191.
18. Herceptin (trastuzumab) [package insert]. South San Francisco, CA: Genentech; 2005.
19. Porterfield LM. Did a monoclonal antibody cause this patient's death? RN. 2000;63:119.
20. Vallhonrat H, Williams WW, Cosimi AB, et al. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Transplantation. 1999;67:253-258.
21. Charpentier B, Hiesse C, Ferran C, et al. Acute clinical syndrome associated with OKT3 administration: prevention by single injection of an anti-human TNF monoclonal antibody [in French]. Presse Med. 1991;20:2009-2011.
22. Charpentier B, Hiesse C, Lantz O, et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation. 1992;54:997-1002.
23. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13(suppl 4):16-22.